Hub : Traits :

Neuroticism

893 significantly associated models · 160 unique genes.

Significant Loci

#	chr	p0	p1	# assoc genes	# joint genes	best TWAS P	best SNP P	cond SNP P	% var exp	joint genes
1	1	7715776	9571422	1	1	1.2e-07	2.8e-07	3.5e-01	97	RERE
2	1	86635245	88077288	1	1	2.6e-07	9.6e-05	1.5e-04	5	SEP15
3	1	171053153	172474017	1	1	7.6e-11	4.6e-09	6.7e-03	79	METTL13
4	1	173103273	174525917	1	1	1.2e-07	2.9e-08	1.2e-02	79	DARS2
5	1	201252866	202669883	1	1	1.4e-07	4.4e-07	2.5e-05	30	RNPEP
6	1	226385623	227873074	1	1	1.7e-07	8.6e-07	2.5e-02	79	ADCK3
7	2	23453834	24924438	1	1	8.4e-08	1.5e-07	2.5e-02	82	UBXN2A
8	2	86061013	87557137	3	1	3.7e-09	2.9e-08	3.3e-02	85	PLGLB1
9	2	147993969	149475737	2	2	1.7e-15	3.7e-17	8.8e-02	96	ORC4 ORC4L
10	2	172084299	173544743	1	1	9.1e-08	6.4e-07	5.4e-02	85	HAT1
11	3	16154636	17814553	1	1	8.1e-10	1.2e-10	1.0e+00	100	PLCL2
12	3	35439546	36079910	1	1	6.7e-11	3.3e-12	5.4e-03	84	ARPP21
13	3	48702606	51043528	5	2	1.7e-09	4.1e-07	1.0e+00	100	GPX1 U73166.2
14	3	51860817	53489090	2	1	6.9e-08	6.6e-08	1.0e+00	100	NT5DC2
15	3	84767271	86367480	1	1	1.1e-07	5.6e-08	6.8e-02	89	CADM2
16	3	135273949	137423165	6	1	1.4e-12	3.0e-12	1.0e+00	100	STAG1
17	4	14777384	16291144	1	1	1.8e-07	1.3e-06	1.0e-02	72	CC2D2A
18	4	41416242	42851723	1	1	2.2e-07	1.6e-07	5.6e-02	87	BEND4
19	4	89947254	91439574	1	1	7.1e-09	1.7e-09	1.0e+00	100	SNCA
20	5	86867897	88677293	4	3	2.9e-12	9.1e-11	7.3e-01	100	LINC00461 LOC645323 TMEM161B
21	7	1580921	2977732	1	1	6.9e-08	5.4e-09	6.1e-04	66	FTSJ2
22	7	11553163	12967449	1	1	1.0e-07	7.4e-08	8.8e-02	90	TMEM106B
23	7	31804088	33193481	1	1	4.8e-08	3.0e-07	4.7e-02	85	AC018641.7
24	7	125383444	127590914	1	1	2.2e-09	2.9e-12	7.7e-06	59	GRM8
25	7	136676570	137272621	1	1	1.9e-07	7.6e-07	2.3e-02	79	PTN
26	7	154388677	155777228	1	1	1.7e-08	8.4e-09	1.0e+00	100	AC144652.1
27	8	94046312	95443806	1	1	1.2e-08	2.9e-07	9.7e-01	100	RP11-10N23.4
28	9	95502571	96898436	1	1	2.2e-08	3.4e-09	7.2e-06	42	RP11-165J3.6
29	9	97520168	98975128	1	1	2.7e-10	3.8e-12	3.7e-03	82	PTCH1
30	9	119768572	121177842	1	1	1.9e-10	9.6e-12	5.8e-04	74	TLR4
31	9	126771321	128824378	5	2	1.2e-08	2.8e-08	1.0e+00	100	NEK6 PPP6C
32	9	136197834	137631198	1	1	6.9e-08	7.7e-06	5.5e-06	-3	BRD3
33	10	103905779	105647095	4	1	1.2e-08	6.7e-09	1.0e+00	100	CNNM2
34	11	9105636	11013472	1	1	2.7e-07	2.7e-07	1.5e-02	78	SBF2
35	11	12611333	14105497	1	1	3.9e-13	1.5e-12	1.2e-01	95	ARNTL
36	11	31573646	32085420	1	1	1.8e-10	7.4e-13	1.4e-05	63	PAX6
37	11	46010847	48559571	14	7	2.6e-13	6.7e-11	NaN	NaN	ARHGAP1 C1QTNF4 LRP4 MADD MTCH2 NUP160
38	11	56666189	58178587	4	1	4.0e-12	6.1e-12	1.0e+00	100	ZDHHC5
39	11	77215675	78828001	2	1	4.4e-09	3.8e-08	7.5e-02	90	GAB2
40	11	112135760	113969669	5	6	2.3e-18	2.5e-19	NaN	NaN	ANKK1 DRD2 NCAM1 TTC12
41	11	133079948	134525648	1	1	7.2e-09	3.8e-10	1.3e-02	84	IGSF9B
42	12	108763672	110729807	5	1	1.6e-12	1.9e-12	1.2e-01	95	KCTD10
43	12	118116461	119551378	2	1	7.8e-12	1.8e-11	2.3e-01	97	TAOK3
44	12	120636549	121146219	1	1	1.2e-07	1.0e-05	2.3e-01	93	GATC
45	13	66643767	68053176	1	1	1.9e-08	2.1e-08	2.3e-06	29	PCDH9
46	13	98409084	99925872	1	1	5.3e-08	1.8e-08	1.3e-02	80	STK24
47	14	69027866	70518587	2	1	5.8e-09	1.0e-09	4.9e-02	90	DCAF5
48	14	74245607	76226003	7	1	7.5e-16	1.2e-14	9.6e-03	89	RPS6KL1
49	15	67138238	68789191	2	1	1.8e-08	7.1e-09	1.0e+00	100	MAP2K5
50	15	77207277	78806023	1	1	3.1e-07	7.1e-09	2.5e-04	60	LINGO1
51	16	30347731	31833122	8	1	1.1e-09	3.5e-09	2.4e-01	96	STX1B
52	16	86667409	89448663	4	3	2.4e-08	9.4e-10	1.3e-04	61	MAP1LC3B MVD SNAI3-AS1
53	17	1805677	3287175	1	1	1.4e-07	5.5e-11	6.0e-06	52	PAFAH1B1
54	17	7846684	8340866	1	1	2.8e-07	5.3e-07	1.3e-01	91	C17orf59
55	17	37931220	38453334	1	1	8.2e-08	3.0e-08	6.3e-02	89	MED24
56	17	42607368	45796313	21	1	5.8e-28	1.4e-26	5.0e-02	97	WNT3
57	17	78843139	79380547	1	1	1.6e-10	2.4e-12	3.2e-03	82	AATK
58	18	30921425	31568499	1	1	5.6e-11	3.1e-10	1.5e-01	95	ASXL3
59	18	34124783	35844220	1	2	3.7e-09	1.2e-18	6.7e-07	68	CELF4
60	18	52209411	54028036	1	1	5.4e-12	1.1e-14	5.8e-07	58	TCF4
61	19	45799442	47218599	1	1	3.0e-08	2.5e-08	1.6e-01	94	CCDC61
62	20	17776692	19441650	4	1	3.5e-08	6.2e-08	4.0e-01	98	DTD1
63	20	32594714	34109427	1	1	1.4e-07	1.3e-06	6.7e-01	99	NCOA6
64	20	43958786	45456440	2	1	6.5e-11	1.3e-09	5.3e-03	79	CD40
65	22	40472399	42614362	4	1	6.8e-10	1.1e-10	5.4e-02	91	RANGAP1

Pleiotropic Associations

Trait	chisq ratio	# genes⁺	# genes⁺⁺	% genes⁺⁺	corr	corr P	genes
Bipolar Disorder (2018)	1.6	1	0	0.0	0.00	1.0e+00	MED24
Bipolar Disorder or Schizophrenia	2.1	3	1	2.2	0.00	1.0e+00	CNNM2 MED24 NT5DC2
Depressed Affect (Nagel 2018)	11.5	58	30	66.7	0.98	2.7e-46	AATK AC144652.1 ANKK1 ARHGAP1 ARNTL ARPP21 ASXL3 BRD3 C1QTNF4 CC2D2A CD40 CELF4 DARS2 DCAF5 DRD2 FTSJ2 GPX1 GRM8 HAT1 KCTD10 LINC00461 LINGO1 LOC645323 LRP4 MADD MED24 METTL13 MTCH2 MVD NCAM1 NEK6 NUP160 ORC4 ORC4L PAFAH1B1 PCDH9 PLCL2 PTCH1 PTN RANGAP1 RERE RNPEP RP11-165J3.6 RPS6KL1 SEP15 SNAI3-AS1 SNCA STAG1 STX1B TAOK3 TCF4 TLR4 TMEM106B TMEM161B TTC12 UBXN2A WNT3 ZDHHC5
Depression (Nagel 2018)	7.6	21	6	13.3	0.97	2.6e-13	AATK ANKK1 C1QTNF4 CELF4 DCAF5 FTSJ2 MADD NCAM1 NUP160 PCDH9 RERE RP11-165J3.6 SNCA STAG1 TAOK3 TMEM106B TTC12 U73166.2 UBXN2A WNT3 ZDHHC5
Intelligence (Savage-Jansen 2018)	2.7	15	8	17.8	-0.22	4.1e-01	AATK C1QTNF4 DARS2 GPX1 LINC00461 MAP1LC3B METTL13 MTCH2 NCAM1 NT5DC2 NUP160 PLCL2 STAG1 WNT3 ZDHHC5
Neuroticism (Nagel 2018)	14.5	77	52	115.6	1.00	6.7e-82	AATK AC018641.7 AC144652.1 ADCK3 ANKK1 ARHGAP1 ARNTL ARPP21 ASXL3 BEND4 BRD3 C1QTNF4 CADM2 CC2D2A CD40 CELF4 CNNM2 DARS2 DCAF5 DRD2 DTD1 FTSJ2 GAB2 GPX1 GRM8 HAT1 IGSF9B KCTD10 LINC00461 LINGO1 LOC645323 LRP4 MADD MAP1LC3B MAP2K5 MED24 METTL13 MTCH2 MVD NCAM1 NCOA6 NEK6 NT5DC2 NUP160 ORC4 ORC4L PAFAH1B1 PAX6 PCDH9 PLCL2 PLGLB1 PPP6C PTCH1 PTN RANGAP1 RERE RNPEP RP11-10N23.4 RP11-165J3.6 RPS6KL1 SBF2 SEP15 SNAI3-AS1 SNCA STAG1 STK24 STX1B TAOK3 TCF4 TLR4 TMEM106B TMEM161B TTC12 U73166.2 UBXN2A WNT3 ZDHHC5
Schizophrenia (2018)	2.3	5	2	4.4	0.63	2.6e-01	CNNM2 IGSF9B RERE STAG1 ZDHHC5
Schizophrenia vs Biploar Disorder	1.9	3	0	0.0	0.00	1.0e+00	ARNTL CNNM2 MED24
Worry (Nagel 2018)	10.7	52	27	60.0	0.98	3.4e-38	AATK ADCK3 ANKK1 ARNTL ARPP21 ASXL3 BRD3 C17orf59 C1QTNF4 CADM2 CELF4 CNNM2 DARS2 DRD2 DTD1 HAT1 IGSF9B KCTD10 LOC645323 MADD MAP1LC3B MAP2K5 MED24 METTL13 MTCH2 NCAM1 NCOA6 NEK6 NT5DC2 NUP160 ORC4 ORC4L PAX6 PLCL2 PLGLB1 PPP6C PTCH1 RANGAP1 RP11-165J3.6 RPS6KL1 SBF2 SNAI3-AS1 SNCA STAG1 STK24 STX1B TMEM106B TMEM161B TTC12 U73166.2 WNT3 ZDHHC5
Alzheimer’s Disease (including proxy)	1.8	2	0	0.0	0.00	1.0e+00	C1QTNF4 MADD
Crohns Disease (2017)	1.0	2	1	2.2	0.00	1.0e+00	CD40 GPX1
Irritable Bowel Disease (IBD)	1.3	2	1	2.2	0.00	1.0e+00	CD40 GPX1
Ulcerative Colitis (UC)	1.3	2	1	2.2	0.00	1.0e+00	GPX1 MED24
Major Depression (MDD)	4.3	7	0	0.0	0.99	5.2e-06	BEND4 CNNM2 GPX1 TAOK3 TCF4 TMEM106B ZDHHC5
Reaction Time	1.9	4	1	2.2	-0.60	4.0e-01	ARHGAP1 HAT1 LRP4 MED24
Verbal and Numeric Reasoning (VNR)	2.6	10	3	6.7	-0.08	8.2e-01	C17orf59 C1QTNF4 GPX1 LINC00461 MAP1LC3B METTL13 MTCH2 NCAM1 NT5DC2 NUP160
Breast Cancer	1.2	2	1	2.2	0.00	1.0e+00	SBF2 WNT3
Ovarian Cancer	1.1	1	1	2.2	0.00	1.0e+00	WNT3
Prostate Cancer	1.6	1	0	0.0	0.00	1.0e+00	GPX1
Age at First Birth	1.7	1	1	2.2	0.00	1.0e+00	GPX1
Body Mass Index (BMI) (2010)	2.8	5	3	6.7	-0.99	3.2e-04	C1QTNF4 CNNM2 MADD MAP2K5 MTCH2
Coronary Artery Disease (CAD)	1.5	1	0	0.0	0.00	1.0e+00	CNNM2
Mean Putamen Volume	1.2	1	0	0.0	0.00	1.0e+00	WNT3
Fasting Glucose	1.5	1	1	2.2	0.00	1.0e+00	MADD
HDL Cholesterol	2.5	6	3	6.7	0.51	2.4e-01	ARHGAP1 C1QTNF4 KCTD10 LRP4 MTCH2 NUP160
LDL Cholesterol	1.2	1	0	0.0	0.00	1.0e+00	C17orf59
Neuroticism (2016)	7.8	18	2	4.4	0.98	9.1e-14	C1QTNF4 CELF4 DRD2 GPX1 LINC00461 MADD MTCH2 PAX6 PCDH9 RANGAP1 RPS6KL1 SBF2 STK24 TAOK3 TCF4 TLR4 U73166.2 WNT3
Primary Biliary Cirrhosis	1.2	2	0	0.0	0.00	1.0e+00	PLCL2 WNT3
Rheumatoid Arthritis	1.4	1	0	0.0	0.00	1.0e+00	CD40
Schizophrenia (2014)	2.4	6	2	4.4	0.69	1.3e-01	CNNM2 DRD2 IGSF9B RERE STAG1 ZDHHC5
Triglycerides	1.0	1	0	0.0	0.00	1.0e+00	NCOA6
Ulcerative Colitis	1.4	1	1	2.2	0.00	1.0e+00	GPX1
Blood Eosinophil Count	1.3	12	7	15.6	-0.48	1.1e-01	BRD3 GPX1 KCTD10 MAP2K5 MED24 NEK6 ORC4 ORC4L PLCL2 RANGAP1 RERE WNT3
Blood Platelet Count	1.1	17	13	28.9	0.35	1.5e-01	AC144652.1 BRD3 C1QTNF4 GAB2 LINC00461 MADD MED24 METTL13 MTCH2 NCOA6 NEK6 NT5DC2 RPS6KL1 SNAI3-AS1 STAG1 U73166.2 ZDHHC5
Blood Red Count	2.1	22	15	33.3	0.19	4.0e-01	ARNTL BRD3 C17orf59 CC2D2A CNNM2 DARS2 DCAF5 DRD2 GAB2 LINC00461 METTL13 MTCH2 MVD NCOA6 NT5DC2 SBF2 SNAI3-AS1 STX1B TMEM161B UBXN2A WNT3 ZDHHC5
Blood White Count	3.4	17	10	22.2	0.06	8.0e-01	AATK C17orf59 C1QTNF4 CNNM2 GPX1 MADD MAP2K5 MED24 MTCH2 NEK6 NUP160 PTCH1 RERE SNAI3-AS1 TMEM161B UBXN2A WNT3
Heel T-Score	1.9	13	7	15.6	-0.14	6.5e-01	ADCK3 ARHGAP1 CNNM2 DTD1 GAB2 LRP4 MADD NCOA6 NEK6 RANGAP1 RERE WNT3 ZDHHC5
BMI	3.3	21	12	26.7	-0.24	2.7e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 CADM2 CNNM2 FTSJ2 GAB2 GPX1 HAT1 LINC00461 MADD MAP2K5 MTCH2 NUP160 PLGLB1 STK24 STX1B TLR4 TTC12
Height	1.5	31	25	55.6	-0.08	6.4e-01	AATK AC018641.7 BRD3 C17orf59 C1QTNF4 FTSJ2 GAB2 GATC GPX1 MADD METTL13 MTCH2 MVD NCOA6 NT5DC2 NUP160 ORC4L PAFAH1B1 PTCH1 RERE RP11-165J3.6 RPS6KL1 SBF2 SNAI3-AS1 SNCA STAG1 TCF4 TMEM106B U73166.2 UBXN2A WNT3
Waist Hip Ratio (WHR)	1.7	10	7	15.6	0.60	5.2e-02	CC2D2A GPX1 NT5DC2 PPP6C SBF2 STAG1 TTC12 U73166.2 UBXN2A WNT3
Systolic Blood Pressure	3.0	17	14	31.1	0.55	1.8e-02	ARHGAP1 ARNTL C17orf59 C1QTNF4 CADM2 CNNM2 GPX1 LRP4 MADD MTCH2 NEK6 ORC4L PAFAH1B1 PPP6C RERE RPS6KL1 ZDHHC5
Smoking Status	2.7	9	4	8.9	0.10	8.0e-01	AATK CADM2 GPX1 MAP1LC3B MAP2K5 NUP160 PPP6C RERE WNT3
Allergy or Eczema	1.6	6	1	2.2	0.21	6.9e-01	BEND4 MED24 NEK6 PLCL2 RANGAP1 RERE
Cardiovascular Disease	1.9	8	2	4.4	0.11	7.9e-01	ANKK1 ARNTL CNNM2 FTSJ2 MAP2K5 RERE STX1B TTC12
Hypothyroidism (self reported)	1.4	3	0	0.0	0.00	1.0e+00	C1QTNF4 MTCH2 RERE
Respiratory disease	1.8	4	2	4.4	0.65	3.5e-01	MED24 MVD RERE SNAI3-AS1
Type 2 Diabetes (T2D) (2018)	1.2	1	0	0.0	0.00	1.0e+00	C1QTNF4
Lung FEV1/FVC ratio	1.2	7	4	8.9	-0.22	6.4e-01	ADCK3 GAB2 PTCH1 RERE RPS6KL1 SBF2 ZDHHC5
Lung FVC	2.1	10	6	13.3	-0.52	1.2e-01	GPX1 MAP2K5 MVD PTCH1 SNAI3-AS1 STX1B TCF4 U73166.2 UBXN2A WNT3
Chronotype (morning person)	1.9	4	1	2.2	-0.61	3.9e-01	C1QTNF4 GAB2 TMEM161B U73166.2
Hair Pigment	1.7	9	7	15.6	0.42	2.6e-01	ADCK3 GAB2 MAP1LC3B MVD NCOA6 RANGAP1 SBF2 SNAI3-AS1 WNT3
Tanning	2.8	8	4	8.9	-0.38	3.1e-01	C1QTNF4 CADM2 GAB2 MAP1LC3B MTCH2 MVD NCOA6 SNAI3-AS1
Hand grip strength (left)	2.7	11	5	11.1	0.09	7.8e-01	ADCK3 ARPP21 BRD3 C1QTNF4 IGSF9B LINGO1 MADD MTCH2 RPS6KL1 TCF4 WNT3
Number of treatments/medications taken	2.8	4	1	2.2	0.96	4.2e-02	DARS2 FTSJ2 GPX1 RPS6KL1
Sensitivity / hurt feelings	7.1	21	8	17.8	0.97	7.3e-14	ANKK1 CELF4 DCAF5 DRD2 GRM8 KCTD10 METTL13 NCAM1 NEK6 ORC4 ORC4L PLCL2 PPP6C PTCH1 RP11-165J3.6 STAG1 TAOK3 TMEM161B TTC12 WNT3 ZDHHC5
Frequency of depressed mood in last 2 weeks	7.2	20	1	2.2	0.97	1.8e-13	AATK C1QTNF4 CC2D2A CELF4 DRD2 MADD NCAM1 NUP160 PCDH9 RERE RP11-10N23.4 RP11-165J3.6 STAG1 STK24 TAOK3 TMEM106B U73166.2 UBXN2A WNT3 ZDHHC5
Hearing difficulty/problems: Yes	1.5	1	0	0.0	0.00	1.0e+00	KCTD10
Relative age of first facial hair	1.8	1	1	2.2	0.00	1.0e+00	WNT3
Other serious medical condition/disability diagnosed by doctor	2.2	2	0	0.0	0.99	7.9e-03	ANKK1 TTC12
Systolic blood pressure, automated reading	2.4	9	4	8.9	0.19	6.3e-01	ARNTL CNNM2 GPX1 LRP4 MADD PAFAH1B1 PPP6C RERE ZDHHC5
Eye problems/disorders: Diabetes related eye disease	1.7	1	0	0.0	0.00	1.0e+00	C1QTNF4
Medication: Metformin	1.4	2	0	0.0	0.00	1.0e+00	C1QTNF4 MTCH2
Severe depression (siblings)	2.1	1	0	0.0	0.00	1.0e+00	PTN
Pack years adult smoking proportion	2.1	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of leg (right)	2.0	16	8	17.8	0.57	2.0e-02	ADCK3 BEND4 C1QTNF4 CNNM2 GPX1 LINC00461 MADD NCOA6 NT5DC2 PPP6C PTCH1 RPS6KL1 SBF2 SNAI3-AS1 U73166.2 UBXN2A
Leg fat-free mass (left)	1.3	11	5	11.1	-0.59	5.8e-02	C1QTNF4 CADM2 CNNM2 HAT1 LINC00461 MAP2K5 NCOA6 PPP6C PTCH1 SBF2 SNAI3-AS1
Trunk fat percentage	3.5	22	11	24.4	-0.21	3.3e-01	ANKK1 ARNTL ARPP21 BEND4 C1QTNF4 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RANGAP1 RERE RPS6KL1 SBF2 STK24 STX1B TTC12 UBXN2A WNT3 ZDHHC5
Hand grip strength (right)	1.9	8	3	6.7	0.23	5.6e-01	ARPP21 BRD3 C1QTNF4 IGSF9B LINGO1 MADD MTCH2 WNT3
Townsend deprivation index at recruitment	2.2	2	0	0.0	0.00	1.0e+00	MAP2K5 MTCH2
Current tobacco smoking	2.7	7	1	2.2	0.74	3.7e-02	AATK C1QTNF4 CELF4 MTCH2 NUP160 PPP6C RANGAP1
Fed-up feelings	7.2	25	10	22.2	0.98	1.2e-16	AC144652.1 ARHGAP1 ARNTL CD40 CELF4 DCAF5 DRD2 GPX1 LINC00461 LINGO1 LRP4 MADD MVD NCAM1 ORC4 ORC4L PAFAH1B1 PCDH9 RPS6KL1 SEP15 STAG1 TLR4 UBXN2A WNT3 ZDHHC5
Frequency of unenthusiasm / disinterest in last 2 weeks	6.1	11	1	2.2	0.98	1.6e-07	ANKK1 CELF4 DCAF5 DRD2 IGSF9B PCDH9 STAG1 TTC12 U73166.2 UBXN2A ZDHHC5
Relative age voice broke	1.6	1	1	2.2	0.00	1.0e+00	WNT3
Taking other prescription medications	2.9	2	1	2.2	0.00	1.0e+00	GPX1 RPS6KL1
Age when periods started (menarche)	2.5	9	6	13.3	0.81	4.1e-03	ARNTL BRD3 C1QTNF4 GAB2 GPX1 MADD MAP2K5 MTCH2 NUP160
Heel bone mineral density (BMD) T-score, automated (left)	1.5	5	3	6.7	-0.46	4.3e-01	ADCK3 ARHGAP1 LRP4 RANGAP1 RERE
Qualifications: CSEs or equivalent	1.1	1	0	0.0	0.00	1.0e+00	WNT3
High blood pressure	1.9	7	3	6.7	0.19	6.9e-01	ARHGAP1 ARNTL CNNM2 LRP4 MADD MAP2K5 RERE
Hayfever, allergic rhinitis or eczema	1.6	4	1	2.2	0.37	6.3e-01	BEND4 MED24 NEK6 RERE
Sitting height	2.0	15	12	26.7	0.06	8.2e-01	AATK BRD3 C1QTNF4 MADD MTCH2 NCOA6 NT5DC2 NUP160 PPP6C PTCH1 SBF2 SNAI3-AS1 UBXN2A WNT3 ZDHHC5
High blood pressure (mother)	1.5	1	1	2.2	0.00	1.0e+00	CNNM2
Body mass index (BMI)	3.1	14	11	24.4	-0.38	1.6e-01	AC018641.7 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 STK24 STX1B
Impedance of leg (left)	1.9	16	8	17.8	0.49	5.3e-02	ADCK3 BEND4 C1QTNF4 CNNM2 GPX1 LINC00461 MADD NCOA6 NT5DC2 PPP6C RPS6KL1 SBF2 SNAI3-AS1 U73166.2 UBXN2A WNT3
Leg predicted mass (left)	1.3	11	5	11.1	-0.59	5.8e-02	C1QTNF4 CADM2 CNNM2 HAT1 LINC00461 MAP2K5 NCOA6 PPP6C PTCH1 SBF2 SNAI3-AS1
Trunk fat mass	2.7	16	7	15.6	-0.35	1.7e-01	ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 GPX1 LINC00461 MADD MAP2K5 MTCH2 RANGAP1 RERE STK24 STX1B TTC12 WNT3
Waist circumference	2.5	13	7	15.6	-0.16	5.5e-01	ANKK1 ARNTL ARPP21 C1QTNF4 FTSJ2 LINC00461 MADD MAP2K5 MTCH2 PTN STK24 STX1B TTC12
Past tobacco smoking	2.0	4	1	2.2	-0.26	7.4e-01	C17orf59 CADM2 MAP2K5 PPP6C
Alcohol usually taken with meals	2.3	3	1	2.2	0.00	1.0e+00	CELF4 DARS2 ZDHHC5
Nervous feelings	7.1	27	8	17.8	0.98	1.8e-18	ADCK3 ANKK1 ARNTL ASXL3 C1QTNF4 CADM2 CELF4 CNNM2 DTD1 KCTD10 LOC645323 MADD NCOA6 ORC4 ORC4L PPP6C PTN RPS6KL1 SBF2 SNCA STAG1 STK24 STX1B TMEM161B TTC12 U73166.2 WNT3
Frequency of tenseness / restlessness in last 2 weeks	6.4	14	3	6.7	0.99	1.4e-10	AATK ANKK1 CELF4 CNNM2 DRD2 GPX1 KCTD10 NT5DC2 RP11-165J3.6 STAG1 TMEM106B TTC12 UBXN2A WNT3
Hearing difficulty/problems with background noise	2.8	5	0	0.0	0.97	7.7e-03	ARHGAP1 KCTD10 LRP4 PAFAH1B1 WNT3
Hair/balding pattern: Pattern 2	1.4	1	1	2.2	0.00	1.0e+00	WNT3
Forced vital capacity (FVC)	2.3	8	7	15.6	0.05	8.9e-01	C1QTNF4 GPX1 MTCH2 NUP160 PTCH1 SNAI3-AS1 STX1B WNT3
Heel bone mineral density (BMD) T-score, automated (right)	1.7	4	3	6.7	-0.50	5.0e-01	ADCK3 ARHGAP1 LRP4 RERE
Ever unenthusiastic/disinterested for a whole week	2.2	1	0	0.0	0.00	1.0e+00	WNT3
Qualifications: None of the above	2.0	4	1	2.2	-0.45	5.5e-01	CELF4 GPX1 LOC645323 TMEM161B
Financial difficulties in last 2 years	2.2	1	0	0.0	0.00	1.0e+00	DRD2
Mouth/teeth dental problems	1.8	2	0	0.0	0.00	1.0e+00	KCTD10 WNT3
Allergy	1.7	5	2	4.4	-0.62	2.7e-01	KCTD10 MED24 NEK6 RANGAP1 RERE
Fluid intelligence score	2.4	5	2	4.4	0.31	5.5e-01	C1QTNF4 METTL13 MTCH2 NUP160 STAG1
Neuroticism score	13.8	72	41	91.1	0.99	7.7e-75	AATK AC018641.7 AC144652.1 ADCK3 ANKK1 ARHGAP1 ARNTL ARPP21 ASXL3 BEND4 BRD3 C1QTNF4 CADM2 CC2D2A CCDC61 CD40 CELF4 DARS2 DCAF5 DRD2 DTD1 FTSJ2 GPX1 GRM8 IGSF9B KCTD10 LINC00461 LINGO1 LOC645323 LRP4 MADD MAP1LC3B MED24 METTL13 MTCH2 MVD NCAM1 NCOA6 NT5DC2 NUP160 ORC4 ORC4L PAFAH1B1 PAX6 PCDH9 PLCL2 PLGLB1 PPP6C PTCH1 PTN RANGAP1 RERE RNPEP RP11-10N23.4 RP11-165J3.6 RPS6KL1 SBF2 SNAI3-AS1 SNCA STAG1 STK24 STX1B TAOK3 TCF4 TLR4 TMEM106B TMEM161B TTC12 U73166.2 UBXN2A WNT3 ZDHHC5
Weight	1.6	12	6	13.3	-0.44	1.3e-01	ANKK1 ARPP21 C1QTNF4 CNNM2 GPX1 HAT1 LINC00461 MADD MAP2K5 PPP6C STX1B TMEM161B
Impedance of arm (right)	2.0	13	8	17.8	0.37	2.1e-01	ADCK3 CADM2 GAB2 GPX1 NT5DC2 PPP6C RANGAP1 SBF2 TMEM106B TMEM161B U73166.2 WNT3 ZDHHC5
Arm fat percentage (right)	3.9	19	12	26.7	-0.19	4.0e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RERE SBF2 STK24 STX1B TTC12 ZDHHC5
Trunk fat-free mass	1.4	15	8	17.8	-0.26	3.4e-01	ARHGAP1 BRD3 C1QTNF4 CADM2 CNNM2 DARS2 MTCH2 NCOA6 NUP160 PPP6C PTCH1 RPS6KL1 SBF2 TMEM161B UBXN2A
Hip circumference	2.1	12	7	15.6	-0.36	2.2e-01	AC018641.7 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 PPP6C PTCH1 STX1B
Time employed in main current job	1.7	1	1	2.2	0.00	1.0e+00	WNT3
Alcohol intake versus 10 years previously	1.9	1	0	0.0	0.00	1.0e+00	FTSJ2
Father's age at death	1.3	1	0	0.0	0.00	1.0e+00	GPX1
Worrier / anxious feelings	7.5	29	9	20.0	0.98	5.0e-21	ADCK3 ARNTL ARPP21 CADM2 CNNM2 DTD1 IGSF9B KCTD10 LINGO1 LOC645323 METTL13 NT5DC2 ORC4 ORC4L PAX6 PPP6C PTCH1 PTN RANGAP1 RP11-165J3.6 RPS6KL1 STAG1 STX1B TCF4 TLR4 TMEM161B U73166.2 WNT3 ZDHHC5
Frequency of tiredness / lethargy in last 2 weeks	6.3	15	4	8.9	0.98	3.6e-11	AATK AC144652.1 ARHGAP1 DCAF5 GPX1 KCTD10 ORC4L PAFAH1B1 RANGAP1 RP11-165J3.6 SNAI3-AS1 STAG1 TTC12 UBXN2A ZDHHC5
Hair/balding pattern: Pattern 3	1.6	1	1	2.2	0.00	1.0e+00	WNT3
Number of live births	1.3	2	0	0.0	0.00	1.0e+00	CADM2 WNT3
Forced expiratory volume in 1-second (FEV1)	2.2	8	5	11.1	-0.14	7.1e-01	C1QTNF4 GPX1 MTCH2 PPP6C PTCH1 SNAI3-AS1 STX1B WNT3
Pulse rate	1.3	2	0	0.0	0.00	1.0e+00	GAB2 SEP15
Qualifications: A levels/AS levels or equivalent	2.0	4	1	2.2	-0.59	4.1e-01	GPX1 LINC00461 METTL13 RNPEP
Mouth/teeth dental problems: Dentures	1.7	3	0	0.0	0.00	1.0e+00	ADCK3 GPX1 STAG1
Asthma	1.7	3	2	4.4	0.00	1.0e+00	MED24 MVD RERE
Medication: Ibuprofen (e.g. Nurofen)	1.5	1	0	0.0	0.00	1.0e+00	UBXN2A
Depression (self-reported)	3.0	3	0	0.0	0.00	1.0e+00	AC018641.7 RERE TMEM106B
Forced expiratory volume in 1-second (FEV1), Best measure	2.2	7	5	11.1	-0.07	8.7e-01	C1QTNF4 GPX1 MTCH2 PTCH1 SNAI3-AS1 STX1B WNT3
Impedance of arm (left)	1.9	11	8	17.8	0.37	2.6e-01	CADM2 GAB2 GPX1 NT5DC2 PPP6C RANGAP1 SBF2 TMEM161B U73166.2 WNT3 ZDHHC5
Arm fat mass (right)	2.9	15	9	20.0	-0.26	3.0e-01	ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 STK24 STX1B TTC12
Trunk predicted mass	1.4	15	8	17.8	-0.27	3.3e-01	ARHGAP1 BRD3 C1QTNF4 CADM2 CNNM2 DARS2 MTCH2 NCOA6 NUP160 PPP6C PTCH1 RPS6KL1 SBF2 TMEM161B UBXN2A
Standing height	1.7	22	16	35.6	-0.01	9.7e-01	AATK BRD3 C1QTNF4 FTSJ2 GAB2 GPX1 MADD METTL13 MTCH2 NCOA6 NT5DC2 NUP160 PTCH1 RP11-165J3.6 RPS6KL1 SBF2 SNAI3-AS1 SNCA STAG1 TMEM106B UBXN2A WNT3
Tense / 'highly strung'	7.0	23	7	15.6	0.97	2.9e-14	AATK AC144652.1 ADCK3 ANKK1 C17orf59 CADM2 CNNM2 DARS2 DRD2 DTD1 LOC645323 NCOA6 ORC4 ORC4L RANGAP1 RERE RP11-165J3.6 RPS6KL1 STAG1 STX1B TMEM106B TTC12 U73166.2
Seen doctor (GP) for nerves, anxiety, tension or depression	5.8	11	3	6.7	0.97	9.8e-07	ANKK1 ASXL3 CELF4 DRD2 FTSJ2 MED24 RPS6KL1 TCF4 TMEM106B TMEM161B TTC12
Hair/balding pattern: Pattern 4	2.4	1	1	2.2	0.00	1.0e+00	WNT3
Birth weight of first child	1.3	1	0	0.0	0.00	1.0e+00	PAFAH1B1
Peak expiratory flow (PEF)	1.6	2	1	2.2	0.00	1.0e+00	PPP6C WNT3
Qualifications: O levels/GCSEs or equivalent	1.8	2	1	2.2	0.00	1.0e+00	GPX1 PLCL2
Medication: Paracetamol	2.6	4	2	4.4	0.98	1.9e-02	DARS2 GPX1 KCTD10 WNT3
Headache pain in last month	2.7	4	1	2.2	0.99	6.3e-03	NT5DC2 TLR4 WNT3 ZDHHC5
Hypothyroidism/myxoedema (self-reported)	1.2	1	0	0.0	0.00	1.0e+00	RERE
Medication: Ventolin 100micrograms inhaler	1.3	1	0	0.0	0.00	1.0e+00	MED24
Birth weight	1.6	4	2	4.4	0.56	4.4e-01	C1QTNF4 CNNM2 MTCH2 PTCH1
Forced vital capacity (FVC), Best measure	2.4	10	7	15.6	-0.05	8.8e-01	AC018641.7 C1QTNF4 GPX1 LRP4 MTCH2 NUP160 PTCH1 SNAI3-AS1 STX1B WNT3
Body fat percentage	3.7	22	12	26.7	-0.16	4.4e-01	ANKK1 ARNTL ARPP21 BEND4 C1QTNF4 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RANGAP1 RERE RPS6KL1 SBF2 STK24 STX1B TTC12 UBXN2A WNT3 ZDHHC5
Leg fat percentage (right)	3.5	20	11	24.4	-0.03	9.0e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 DCAF5 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RERE RPS6KL1 SBF2 STK24 STX1B TTC12 UBXN2A
Arm fat-free mass (right)	1.3	12	4	8.9	-0.20	5.4e-01	BRD3 CADM2 CNNM2 GPX1 HAT1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 SBF2 TMEM161B
Comparative body size at age 10	3.2	10	7	15.6	-0.97	5.3e-07	C1QTNF4 CADM2 MADD MAP2K5 MTCH2 NUP160 RANGAP1 RP11-165J3.6 STX1B U73166.2
Number of full brothers	1.7	1	0	0.0	0.00	1.0e+00	WNT3
Worry too long after embarrassment	7.3	14	8	17.8	0.96	5.5e-09	ANKK1 ARNTL ARPP21 DRD2 KCTD10 LINC00461 MAP2K5 NCAM1 NCOA6 PPP6C STAG1 TTC12 WNT3 ZDHHC5
Seen a psychiatrist for nerves, anxiety, tension or depression	3.4	1	0	0.0	0.00	1.0e+00	TMEM106B
Wheeze or whistling in the chest in last year	2.5	5	0	0.0	0.66	2.3e-01	GPX1 MED24 MVD RERE SNAI3-AS1
Number of children fathered	1.3	1	0	0.0	0.00	1.0e+00	CADM2
Age at first live birth	2.0	2	1	2.2	0.00	1.0e+00	CELF4 GPX1
Health satisfaction	2.5	3	0	0.0	0.00	1.0e+00	ANKK1 DRD2 PCDH9
Qualifications: College or University degree	2.6	11	7	15.6	-0.43	1.7e-01	CELF4 DARS2 DCAF5 FTSJ2 GPX1 LINC00461 LOC645323 STK24 TMEM161B WNT3 ZDHHC5
Emphysema/chronic bronchitis	1.8	1	0	0.0	0.00	1.0e+00	MED24
Medication for pain relief, constipation, heartburn	2.5	6	2	4.4	-0.94	5.8e-03	DARS2 GPX1 PCDH9 RP11-165J3.6 RPS6KL1 WNT3
Neck or shoulder pain in last month	2.4	2	1	2.2	0.00	1.0e+00	ASXL3 GPX1
Mean time to correctly identify matches	2.0	3	2	4.4	0.00	1.0e+00	ARHGAP1 HAT1 LRP4
Whole body fat mass	2.8	15	8	17.8	-0.24	3.4e-01	ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 RERE STK24 STX1B TTC12
Leg fat mass (right)	2.9	17	8	17.8	-0.18	4.4e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 RERE STK24 STX1B TMEM161B TTC12
Arm predicted mass (right)	1.3	12	5	11.1	-0.20	5.4e-01	BRD3 CADM2 CNNM2 GPX1 HAT1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 SBF2 TMEM161B
Pulse rate, automated reading	1.5	6	0	0.0	0.68	1.4e-01	DARS2 GAB2 LINC00461 ORC4L SBF2 ZDHHC5
Alcohol intake frequency.	3.5	10	7	15.6	-0.14	6.8e-01	C1QTNF4 CADM2 DRD2 LOC645323 MADD MTCH2 TCF4 TMEM161B WNT3 ZDHHC5
Comparative height size at age 10	1.4	15	7	15.6	-0.07	8.0e-01	ANKK1 C1QTNF4 GPX1 KCTD10 METTL13 MTCH2 NCOA6 NT5DC2 NUP160 PTCH1 RPS6KL1 SNCA STAG1 TCF4 WNT3
Suffer from 'nerves'	7.7	13	6	13.3	0.93	1.9e-06	AATK ANKK1 ARHGAP1 C1QTNF4 CADM2 DTD1 MADD MTCH2 NUP160 RERE RPS6KL1 TTC12 WNT3
Overall health rating	3.8	7	4	8.9	0.98	6.7e-06	AATK ANKK1 DCAF5 GPX1 NCAM1 RP11-165J3.6 TTC12
Chest pain or discomfort	2.6	3	0	0.0	0.00	1.0e+00	AC144652.1 ASXL3 MED24
Age at last live birth	1.8	2	1	2.2	0.00	1.0e+00	DTD1 GPX1
Leg pain on walking	1.5	1	0	0.0	0.00	1.0e+00	WNT3
Supplements: Vitamin C	1.3	1	0	0.0	0.00	1.0e+00	WNT3
Knee pain experienced in last month	1.9	1	0	0.0	0.00	1.0e+00	DARS2
Hypertension (Self-reported)	1.8	7	1	2.2	0.16	7.4e-01	ARHGAP1 ARNTL CNNM2 LRP4 MADD MAP2K5 RERE
Illnesses of father: Heart disease	1.1	1	0	0.0	0.00	1.0e+00	WNT3
Smoking status: Previous	1.7	1	1	2.2	0.00	1.0e+00	CADM2
Forced expiratory volume in 1-second (FEV1), predicted	1.3	2	0	0.0	0.00	1.0e+00	C1QTNF4 PTCH1
Whole body fat-free mass	1.3	13	7	15.6	-0.39	1.9e-01	BRD3 CADM2 CNNM2 HAT1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 RPS6KL1 SBF2 TMEM161B UBXN2A
Leg fat-free mass (right)	1.4	12	6	13.3	-0.44	1.5e-01	BRD3 C1QTNF4 CADM2 CNNM2 HAT1 LINC00461 MAP2K5 NCOA6 PPP6C PTCH1 SBF2 SNAI3-AS1
Arm fat percentage (left)	4.0	18	13	28.9	-0.32	1.7e-01	AC018641.7 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RERE SBF2 STK24 STX1B TTC12 ZDHHC5
Average weekly red wine intake	2.1	3	0	0.0	0.00	1.0e+00	LOC645323 TMEM161B ZDHHC5
Handedness (chirality/laterality): Left-handed	1.6	1	1	2.2	0.00	1.0e+00	WNT3
Mood swings	8.7	28	13	28.9	0.98	1.1e-21	ANKK1 ASXL3 C1QTNF4 CD40 CELF4 DRD2 GPX1 MADD MAP1LC3B METTL13 MTCH2 MVD NCAM1 NUP160 PLCL2 PTN RANGAP1 RP11-165J3.6 RPS6KL1 SNAI3-AS1 SNCA STK24 STX1B TCF4 TLR4 TMEM106B TTC12 WNT3
Loneliness, isolation	6.8	13	5	11.1	0.96	6.9e-08	C1QTNF4 GPX1 MADD MED24 MTCH2 NUP160 ORC4 ORC4L PCDH9 RERE TAOK3 TMEM106B WNT3
Long-standing illness, disability or infirmity	2.2	1	0	0.0	0.00	1.0e+00	ANKK1
Qualifications: nursing, teaching	2.1	2	0	0.0	0.00	1.0e+00	RNPEP STK24
Mouth/teeth dental problems: Mouth ulcers	1.1	1	1	2.2	0.00	1.0e+00	WNT3
Medication for cholesterol	1.5	1	0	0.0	0.00	1.0e+00	STX1B
Mineral and other dietary supplements	1.5	1	0	0.0	0.00	1.0e+00	BEND4
Asthma (self-reported)	1.7	3	2	4.4	0.00	1.0e+00	MED24 MVD RERE
Smoking status: Current	2.6	6	1	2.2	0.74	6.0e-02	AATK C1QTNF4 MTCH2 NUP160 PPP6C RANGAP1
Forced expiratory volume in 1-second (FEV1), predicted percentage	1.6	3	2	4.4	0.00	1.0e+00	IGSF9B STX1B WNT3
Whole body water mass	1.3	14	7	15.6	-0.32	2.6e-01	BRD3 CADM2 CNNM2 GPX1 HAT1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 RPS6KL1 SBF2 TMEM161B UBXN2A
Leg predicted mass (right)	1.3	12	6	13.3	-0.44	1.5e-01	BRD3 C1QTNF4 CADM2 CNNM2 HAT1 LINC00461 MAP2K5 NCOA6 PPP6C PTCH1 SBF2 SNAI3-AS1
Arm fat mass (left)	3.0	16	9	20.0	-0.33	2.0e-01	ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RERE STK24 STX1B TTC12
Number of self-reported non-cancer illnesses	3.0	3	1	2.2	0.00	1.0e+00	ARNTL FTSJ2 TMEM106B
Average weekly champagne plus white wine intake	2.1	1	0	0.0	0.00	1.0e+00	WNT3
Miserableness	9.1	30	15	33.3	0.97	1.7e-19	ANKK1 ARHGAP1 ARNTL ARPP21 C1QTNF4 CD40 CELF4 DRD2 FTSJ2 GPX1 KCTD10 LINGO1 LRP4 MADD METTL13 MTCH2 NCAM1 NUP160 ORC4 ORC4L PAFAH1B1 PCDH9 RP11-165J3.6 SNAI3-AS1 STAG1 TCF4 TMEM106B TTC12 UBXN2A WNT3
Guilty feelings	7.5	18	8	17.8	0.97	5.1e-12	AATK ANKK1 ARNTL ARPP21 C1QTNF4 CD40 DRD2 LINGO1 MADD METTL13 NCAM1 PAFAH1B1 PTCH1 RPS6KL1 TTC12 UBXN2A WNT3 ZDHHC5
Financial situation satisfaction	2.4	2	1	2.2	0.00	1.0e+00	BRD3 GPX1
Medication: Blood pressure	1.6	1	1	2.2	0.00	1.0e+00	CNNM2
Medication: Bendroflumethiazide	1.8	1	0	0.0	0.00	1.0e+00	SNAI3-AS1
Medication: Paracetamol	2.5	3	2	4.4	0.00	1.0e+00	DARS2 GPX1 WNT3
Illnesses of father: High blood pressure	1.4	1	0	0.0	0.00	1.0e+00	MADD
Alcohol drinker status: Never	1.8	1	0	0.0	0.00	1.0e+00	C1QTNF4
Ever smoked	2.1	4	0	0.0	0.57	4.3e-01	AATK C17orf59 CADM2 PPP6C
Basal metabolic rate	1.2	12	7	15.6	-0.34	2.8e-01	BRD3 CADM2 CNNM2 GPX1 HAT1 LINC00461 MAP2K5 NCOA6 PPP6C PTCH1 SBF2 TMEM161B
Leg fat percentage (left)	3.6	19	11	24.4	-0.08	7.3e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 DCAF5 GPX1 LINC00461 MADD MAP2K5 MTCH2 NUP160 RERE RPS6KL1 SBF2 STK24 STX1B TTC12 UBXN2A
Arm fat-free mass (left)	1.3	11	5	11.1	-0.15	6.5e-01	BRD3 CADM2 CNNM2 GPX1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 SBF2 TMEM161B
Number of operations (self-reported)	2.0	1	0	0.0	0.00	1.0e+00	GPX1
Average weekly beer plus cider intake	1.8	1	0	0.0	0.00	1.0e+00	CELF4
Irritability	6.2	18	5	11.1	0.98	6.8e-12	CELF4 DRD2 FTSJ2 GPX1 KCTD10 LINC00461 MVD NCOA6 ORC4 ORC4L PAFAH1B1 PAX6 RANGAP1 SNAI3-AS1 STX1B TCF4 TMEM106B WNT3
Risk taking	1.5	1	1	2.2	0.00	1.0e+00	CADM2
Ever had prostate specific antigen (PSA) test	1.4	2	0	0.0	0.00	1.0e+00	PAFAH1B1 TMEM161B
Fractured/broken bones in last 5 years	1.6	1	0	0.0	0.00	1.0e+00	WNT3
Diastolic blood pressure, automated reading	1.8	8	4	8.9	0.38	3.6e-01	ARNTL CNNM2 GPX1 LINC00461 MADD PAFAH1B1 RERE SBF2
Myopia	1.6	2	0	0.0	0.00	1.0e+00	FTSJ2 MTCH2
Vascular/heart problems diagnosed by doctor	1.8	7	3	6.7	-0.13	7.8e-01	ARHGAP1 ARNTL CNNM2 LRP4 MADD MAP2K5 RERE
Cholesterol lowering medication	1.2	1	0	0.0	0.00	1.0e+00	STX1B
Pain experienced in last month	2.8	4	1	2.2	-0.66	3.4e-01	DARS2 GPX1 KCTD10 STX1B
Basal cell carcinoma (self-reported)	1.4	1	1	2.2	0.00	1.0e+00	NCOA6
Pack years of smoking	2.0	2	0	0.0	0.00	1.0e+00	CELF4 GPX1
Impedance of whole body	1.9	15	11	24.4	0.27	3.3e-01	ADCK3 BEND4 CADM2 CNNM2 GAB2 GPX1 LINC00461 NCOA6 NT5DC2 PPP6C RANGAP1 SBF2 U73166.2 UBXN2A WNT3
Leg fat mass (left)	3.0	18	8	17.8	-0.21	3.6e-01	AC018641.7 ANKK1 ARNTL ARPP21 C1QTNF4 CNNM2 FTSJ2 GPX1 HAT1 LINC00461 MADD MAP2K5 MTCH2 RERE STK24 STX1B TMEM161B TTC12
Arm predicted mass (left)	1.3	11	6	13.3	-0.14	6.9e-01	BRD3 CADM2 CNNM2 GPX1 LINC00461 NCOA6 NUP160 PPP6C PTCH1 SBF2 TMEM161B

Associations by panel

study	tissue	# hits	% hits/tests	avg chisq
GTEx	Adipose Subcutaneous	16	0.46	2.3
GTEx	Adipose Visceral Omentum	12	0.59	2.6
GTEx	Adrenal Gland	11	0.75	2.5
GTEx	Artery Aorta	16	0.54	2.5
GTEx	Artery Coronary	14	1.18	3.0
GTEx	Artery Tibial	18	0.48	2.4
GTEx	Brain Caudate basal ganglia	10	1.09	2.8
GTEx	Brain Cerebellar Hemisphere	10	0.67	2.6
GTEx	Brain Cerebellum	12	0.61	2.5
GTEx	Brain Cortex	13	1.26	3.0
GTEx	Brain Frontal Cortex BA9	8	0.86	2.8
GTEx	Brain Hippocampus	6	1.14	3.2
GTEx	Brain Hypothalamus	5	0.85	2.8
GTEx	Brain Nucleus accumbens basal ganglia	8	0.92	2.9
GTEx	Brain Putamen basal ganglia	6	0.96	2.9
GTEx	Breast Mammary Tissue	18	0.91	2.6
GTEx	Breast Mammary Tissue (Male)	10	0.84	2.6
GTEx	Breast Mammary Tissue (Female)	17	1.03	2.6
GTEx	Cells EBV-transformed lymphocytes	12	0.84	2.9
GTEx	Cells Transformed fibroblasts	18	0.43	2.4
GTEx	Colon Sigmoid	11	0.75	2.6
GTEx	Colon Transverse	19	0.92	2.6
GTEx	Esophagus Gastroesophageal Junction	15	1.04	2.9
GTEx	Esophagus Mucosa	20	0.60	2.4
GTEx	Esophagus Muscularis	20	0.62	2.7
GTEx	Heart Atrial Appendage	15	0.95	2.7
GTEx	Heart Left Ventricle	12	0.78	2.7
GTEx	Liver	7	0.98	2.8
GTEx	Lung	15	0.52	2.5
GTEx	Muscle Skeletal	17	0.59	2.5
GTEx	Nerve Tibial	21	0.49	2.3
GTEx	Ovary	12	1.32	3.1
GTEx	Pancreas	13	0.80	2.6
GTEx	Pituitary	11	0.99	2.6
GTEx	Prostate	10	1.20	2.8
GTEx	Skin Not Sun Exposed Suprapubic	20	0.81	2.7
GTEx	Skin Sun Exposed Lower leg	24	0.66	2.6
GTEx	Small Intestine Terminal Ileum	5	1.08	3.0
GTEx	Spleen	13	0.92	2.8
GTEx	Stomach	12	0.82	2.7
GTEx	Testis	26	0.82	2.6
GTEx	Thyroid	20	0.50	2.4
GTEx	Uterus	9	1.59	3.3
GTEx	Vagina	5	0.79	2.9
GTEx	Whole Blood	13	0.65	2.5
METSIM	Adipose	14	0.30	2.2
NTR	Blood	9	0.37	2.3
ROSMAP	Brain Pre-frontal Cortex	17	0.39	2.3
YFS	Blood	12	0.26	2.1
CommonMind	Brain Pre-frontal Cortex	12	0.22	2.2
The Cancer Genome Atlas	Bladder Urothelial Carcinoma	8	0.48	2.3
The Cancer Genome Atlas	Breast Invasive Carcinoma	15	0.34	2.1
The Cancer Genome Atlas	Cervical Squamous Cell Carcinoma	6	0.54	2.3
The Cancer Genome Atlas	Colon Adenocarcinoma	5	0.24	2.3
The Cancer Genome Atlas	Esophageal Carcinoma	6	0.87	2.8
The Cancer Genome Atlas	Glioblastoma Multiforme	6	0.59	2.5
The Cancer Genome Atlas	Head and Neck Squamous Cell Carcinoma	15	0.55	2.3
The Cancer Genome Atlas	Kidney Renal Clear Cell Carcinoma	16	0.39	2.2
The Cancer Genome Atlas	Kidney Renal Papillary Cell Carcinoma	13	0.63	2.3
The Cancer Genome Atlas	Brain Lower Grade Glioma	12	0.28	2.1
The Cancer Genome Atlas	Liver Hepatocellular Carcinoma	5	0.45	2.2
The Cancer Genome Atlas	Lung Adenocarcinoma	17	0.58	2.2
The Cancer Genome Atlas	Lung Squamous Cell Carcinoma	12	0.48	2.3
The Cancer Genome Atlas	Ovarian Serous Cystadenocarcinoma	11	0.69	2.3
The Cancer Genome Atlas	Pancreatic Adenocarcinoma	5	0.30	2.3
The Cancer Genome Atlas	Pheochromocytoma and Paraganglioma	6	0.45	2.3
The Cancer Genome Atlas	Prostate Adenocarcinoma	19	0.41	2.2
The Cancer Genome Atlas	Rectum Adenocarcinoma	2	0.29	2.2
The Cancer Genome Atlas	Soft Tissue Sarcoma	6	0.56	2.4
The Cancer Genome Atlas	Skin Cutaneous Melanoma	1	0.19	2.0
The Cancer Genome Atlas	Stomach Adenocarcinoma	9	0.53	2.4
The Cancer Genome Atlas	Testicular Germ Cell Tumors	4	0.31	2.2
The Cancer Genome Atlas	Thyroid Carcinoma	23	0.45	2.2
The Cancer Genome Atlas	Uterine Corpus Endometrial Carcinoma	2	0.39	2.3